Why is right heart catheterization not recommended for pulmonary hypertension due to left heart disease?

Why is right heart catheterization not recommended for pulmonary hypertension due to left heart disease?

• A. Because vasodilators are not a treatment option
• B. Because it doesn't provide diagnostic value
• C. Because it's too risky
• D. Because left heart disease is not associated with PH

Answer: (A)

Pulmonary hypertension due to left heart disease is driven by elevated pressures in the left side of the heart, which translates into a post-capillary problem rather than a primary pulmonary vascular disease. Right heart catheterization is useful to measure these pressures and confirm the pattern of PH, helping to distinguish post-capillary from pre-capillary PH. However, testing intravenous or inhaled vasodilators during catheterization to see if the pulmonary pressures fall is not helpful in this setting because there is no proven long-term benefit from pulmonary vasodilator therapy for PH caused by LV disease. In fact, using vasodilators can worsen left-sided edema by increasing blood flow into a poorly compliant left ventricle with high filling pressures. Therefore, the purpose of catheterization in PH-LHD is not to identify a vasodilator-responsive subset, but to assess hemodynamics and guide management of the underlying left heart condition, such as optimizing volume status and heart failure therapies. The other statements don’t fit: PH is indeed associated with left heart disease, and right heart catheterization has diagnostic value even if not for vasodilator responsiveness; while there is some procedural risk, the main reason vasodilator testing isn’t pursued is lack of demonstrated benefit.

Pulmonary hypertension due to left heart disease is driven by elevated pressures in the left side of the heart, which translates into a post-capillary problem rather than a primary pulmonary vascular disease. Right heart catheterization is useful to measure these pressures and confirm the pattern of PH, helping to distinguish post-capillary from pre-capillary PH. However, testing intravenous or inhaled vasodilators during catheterization to see if the pulmonary pressures fall is not helpful in this setting because there is no proven long-term benefit from pulmonary vasodilator therapy for PH caused by LV disease. In fact, using vasodilators can worsen left-sided edema by increasing blood flow into a poorly compliant left ventricle with high filling pressures. Therefore, the purpose of catheterization in PH-LHD is not to identify a vasodilator-responsive subset, but to assess hemodynamics and guide management of the underlying left heart condition, such as optimizing volume status and heart failure therapies. The other statements don’t fit: PH is indeed associated with left heart disease, and right heart catheterization has diagnostic value even if not for vasodilator responsiveness; while there is some procedural risk, the main reason vasodilator testing isn’t pursued is lack of demonstrated benefit.